Lipophilicity determination

Lipophilicity refers to the affinity of a drug for a lipid environment and is a key parameter related to its adequate drug-like properties and off-target effects. It is measured through the tendency of a compound to partition between a lipophilic organic phase and a polar aqueous phase to give logPo/w values. Depending on the compound characteristics different approaches may be applied for its calculation


  • Shake-flask: classical partition method generally applicable, also performed under OECD107 or OECD123 guidelines (under GLP). Under OECD107, the partition experiments in n-octanol/water are performed from the solid compound at three values of pH (logDpH).
  • Chromatography: applicable to unionized compounds, is an approach combining the chromatographic retention of a compound with its hydrogen bond donor properties.
  • Potentiometric titration: applicable to substances with acid-base properties, is performed in a T3 instrument. logPo/w values are obtained from the difference between the aqueous pKa of the species and the apparent pKa determined from dual phase titrations.

Turnaround time: 3 days for logPo/w and 3 weeks for logKow under OECD107 (GLP).

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS